EP-1304: Harmonizing quality assurance procedures and corresponding naming conventions in clinical trials in radiotherapy  by Hurkmans, C.W. et al.
2nd ESTRO Forum 2013   S489 
EP-1303   
Geometric uncertainties due to wobbling effects of the gantry arm 
caused by an add-on micro-MLC of 50 kg 
S.J. Zimmermann1, H.L. Riis1, M. Hjelm-Hansen1 
1Odense University Hospital, Radiofysisk Laboratorium, Odense, 
Denmark  
 
Purpose/Objective: The delivery of high quality stereotactic 
radiosurgery (SRS) and stereotactic radiotherapy (SRT) treatments 
requires knowledge of the position of the isocentre to sub millimetre 
accuracy. The deviation between the radiation and mechanical 
isocentres must be less than 1 mm. The use of an add-on micro-
multileaf collimator (μMLC) in SRS and SRT is an additional challenge 
to the anticipated high-level geometric and dosimetric accuracy of 
the treatment. The aim of this work was to quantify the gantry 
excursions during rotation with and without an add-on μMLC attached 
to the gantry head. In addition, the shift in the position of the 
isocenter and its correlation to the kV beam centre of the cone-beam 
CT system was included in the study. 
Materials and Methods: The quantification of the gantry rotational 
performance was done using a pointer supported by an inhouse made 
rigid holder attached to the gantry head. The pointer positions were 
measured using a digital theodolite. The displacement of the 
isocentre due to an add-on μMLC of 50 kg was investigated. In case of 
the pointer measurement the μMLC was simulated by weights 
attached to the gantry head. A method of least squares was applied to 
determine the position and displacement of the mechanical isocentre. 
Additionally, the displacement of the radiation isocentre was 
measured using a Winston-Lutz phantom and the electronic portal 
image device (EPID) system. These measurements were based on eight 
MV photon beams irradiated onto the ball from the four cardinal 
angles and two opposed collimator angles. The measurements and 
analysis of the data were carried out automatically using software 
delivered by the manufacturer. 
Results: The displacement of the mechanical isocentre caused by a 50 
kg heavy μMLC was found to be (-0.01±0.06, -0.10±0.03, -0.26±0.05) 
mm in lateral, longitudinal and vertical direction, respectively. 
Similarly, the displacement of the radiation isocentre was found to be 
(0.00±0.03, -0.08±0.06, -0.32±0.02) mm. Good agreement was found 
between the displacement of the two isocentres. A displacement of 
the kV cone-beam CT beam centre due to the attached weight of 50 
kg could not be detected. By comparing the CW and CCW data the 
presence of the effect of backlash appears. The effect of backlash 
was found to be < 0.14 mm and < 0.10 mm in the lateral and vertical 
direction, respectively. 
Conclusions: General characteristics of the gantry arm excursions and 
displacements caused by an add-on μMLC have been reported. A 50 kg 
heavy add-on μMLC results in an isocentre displacement downward of 
0.26 to 0.32 mm. We recommend that the beam centre of the kV 
cone-beam CT image system should be matched to the isocentre 
related to the weight of the μMLC. Consequently, the imperfections in 
isocentre localizations are transferred to the conventional 
radiotherapy where the clinical consequences of uncertainties in the 
sub millimetre regime are negligible. 
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Purpose/Objective: Globally, clinical trial groups and organizations 
have independently established and implemented Radiation Therapy 
Quality Assurance (RTQA) procedures within their trials. Recently the 
need for global harmonization of these procedures was identified by 
the Global Clinical Trials RTQA Harmonization Group (GHG – 
www.RTQAHarmonisation.org). Streamlining RTQA procedures would 
increase the accuracy and consistency across international trials, 
improve the cooperation required for intergroup trials, reduce 
investigator and clinical site’s workload and enhance the uniformity of 
result reporting. The outcome of this would allow increase in patient 
recruitment and thus improve the statistical power in trials. The 
purpose of this analysis is to present the various RTQA procedures 
used by the GHG steering committee members and propose a 
harmonization of their naming conventions based on similar RTQA 
objectives. 
Materials and Methods: The GHG consists of a steering committee, 
members and observers. The steering committee includes 
representation from eight organizations and a survey of the GHG 
steering committee members’ RTQA procedures, their goals and 
naming conventions was conducted. RTQA procedures of each GHG 
steering committee member will be presented and defined under the 
following headings: baseline / pre-accrual / during treatment and 
retrospective. A comparison based on the goals of each RTQA 
procedure was performed, in order to identify procedures having a 
different naming convention, but common goals. 
Results: The RTQA procedures required by each group within their 
trials differ in number, timing, name and compliance criteria and are 
all based on perceived chances of non-compliance associated with the 
trial, as well as the expected impact on the quality of the research 
answers being sought. A comparison of the GHG steering committee 
members’ RTQA procedures found similarities in some of the goals, 
but the procedure names were different. After thorough discussions 
with the GHG steering committee members and evaluation of the 
RTQA procedures, the 24 total RTQA procedures were amalgamated to 
11, and a harmonized naming convention has been established (see 
Table 1). 
Conclusions: The need to globally harmonize RTQA in clinical trials 
has been identified and harmonized RTQA naming conventions are 
proposed to be used by the GHG steering committee members in all 
future radiotherapy clinical trials. Adoption of this convention will 
reduce ambiguity and inconsistency in undertaking and reporting 
trials-related RTQA and facilitate greater global collaboration. 
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Purpose/Objective: This work shows that the analysis and existence 
of a treatment interruptions database (TID) may improve the quality 
of the treatments. In particular we act in the prostate cancer (PC) 
treatments with 2Gy/5 weekly fractions. 
Materials and Methods: In our service we have developed a TID to 
facilitate the administration of compensatory measures to each 
patient and to have faster and more effective access to a statistic [1]. 
After 10 months of running (March2011 - January 2012) we have 
analyzed the overall time (OT) prolongation in various treatment 
pathologies. The average prolongation days (APD) for PC (59 
patients,group A) was 6.4 days (CI 95%: 5.2 to 7.5 days). This high 
value is due to the duration of treatment and the habit of not taking 
compensatory measures in PC. To reduce the APD in these cases we 
establish systematic compensatory measures. For low (LR) and 
medium risk (MR) PC a fraction of 3.2Gy is given in the same week of 
the interruptions (equivalent to 2 fractions of2 Gy) and the treatment 
is reduced in 1 fraction; for high risk (HR) PC this measure is given 
only in the boost (due to the great PTV of the base). All the patients 
with PC treated after 1/31/2012 entered in this program (37 
patients,group B). A comparison between the groups was done: APD 
and percentage of the acute effects by grade (PAE) in RTOG scale. 
Finally a radiobiological analysis was done to estimate the benefits of 
this program. It has been estimated an increase of 6% in biochemical 
failure (BF) for 1-week increase in OT [2]. 
Results: The table shows that the two groups are comparable in 
average age. The groups have similar percentages of HR PC, and differ 
in the percentages of LR and MR PC but the sum of these two 
categories (with similar irradiation volumes) are near to each other. 
The differences in the APD are 1.7 days (CI 95%: -0.1,3.7 days), the IC 
almost do not include the zero value, and the t-test is almost 
significant p = 0.058. The smaller size in the group B may have 
influenced this result. It is expected that the difference increases as 
the sample size grows. The PAE grade 2 and 3 are very similar in the 
two groups; there are more patients with grade 1 in the group B and 
less patients without acute effects. 
The estimated improvement in BF is 1.5%.  
 
